PubMed
Permanent URI for this collectionhttps://hdl.handle.net/11452/24864
Browse
Browsing by Author "0000-0001-5555-130X"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
Item Predictors of drug survival of biologic therapies in psoriasis patients(Taylor & Francis Ltd, 2022-01-02) Zorlu, Özge; Bülbül Başkan, Emel; Yazıcı, Serkan; Sığırlı, Deniz; Budak, Ferah; Sarıcaoğlu, Hayriye; Aydoğan, Kenan; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Venereoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.; 0000-0001-5555-130X; 0000-0002-0144-3263; 0000-0001-7625-9148; ABD-1191-2021; AAH-1388-2021; AAH-2459-2021; AAA-7472-2021; F-4657-2014; DPU-8534-2022; AAH-6216-2021; 57203899392; 6602518817; 25925620000; 24482063400; 6701913697; 6603722836; 9739755800Introduction: We aimed to investigate the clinical, immunological, and genetic factors affecting the response to anti-TNF alpha (tumor necrosis factor-alpha) and interleukin-12/23 therapies and drug survivals. Methods: A total of 180 patients were divided into two groups: 89 patients who used at least two biologic agents, with the initial biologic agent used less than 12 months (group A), and 91 biologic-naive patients who have been receiving a single biologic agent for more than 12 months (group B). ELISA (enzyme-linked immunosorbent assay) was used to analyze anti-drug antibodies (ADAs) in blood samples. Clinical data of the patients were retrospectively analyzed. HLA-SSO (sequence-specific oligonucleotide) Typing Kits were used for HLA-C typing. IBM SPSS v.21 was used for statistical analysis. Results: Infliximab had the longest drug survival as the first biologic agent in group A (p = .015). Etanercept had the lowest ADA count compared to the other anti-TNF agents (p = .001). HLA-Cw6 negativity, late-onset psoriasis, smoking and alcohol use were determined to be risk factors for treatment failure in group A. HLA-Cw6 was found to be associated with type I psoriasis (p = .000). Conclusions: Although our study is retrospective of a relatively low number of patients, this is a preliminary study focusing on two different patient populations based on therapy response.